The Phase 1b KEYNOTE-028 trial examined pembrolizumab in PD-L1 positive advanced prostate cancer, reporting an objective response rate of 17.4% and disease control rate of 52.2% (NCT02054806) [33]. The gene discussed is CD274; the disease is prostate carcinoma.